𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The current status of combined modality treatment containing chemotherapy in patients with esophageal cancer

✍ Scribed by Muhy Al-Sarraf

Publisher
Elsevier Science
Year
1990
Tongue
English
Weight
361 KB
Volume
19
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The value of combined-modality therapy i
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer
✍ Steven E. Schild; Sumithra J. Mandrekar; Aminah Jatoi; William L. McGinnis; Phil πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 140 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The objective of this study was to assess the value of combined‐modality therapy in elderly patients by comparing the differences in outcome between patients who received radiotherapy (RT) alone and patients who received RT plus chemotherapy for stage III nonsmall cell l

Combination versus sequential single-age
Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung cancer
✍ Niell, Harvey B. ;Griffin, John P. ;Hunter, Robert F. ;Meredith, Charlotte A. ;S πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 716 KB

We have carried out a randomized phase Ill study in 105 patients with advanced nonsmall cell lung cancer, comparing a fourdrug cisplatin-mitomycin-based combination chemotherapy regimen t o sequential single-agent therapy. The combination chemotherapy regimen consisted of mitomycin C (10 mg/m2), vin

Treatment of newly diagnosed metastatic
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone
✍ Gerald P. Murphy; Sunmolu Beckley; Mark F. Brady; T. Ming Chu; Jean B. Dekernion πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 699 KB

by the National Prostatic Cancer Project randomized newly diagnosed metastatic prostate cancer patients to DES 1 mg orally three times daily or orchiectomy; or DES, 1 mg, three times daily, plus cyclophosphamide at 1 mg/m2 iv every three weeks, or cyclophosphamide 1 g/m2 iv every three weeks plus es

Neck dissection in the combined-modality
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer
✍ Athanassios Argiris; Kerstin M. Stenson; Bruce E. Brockstein; Bharat B. Mittal; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 189 KB πŸ‘ 2 views

## Abstract ## Purpose. The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck. ## Methods. We identified patients with N2–N3 head and neck cancers who were enrolled in three consecutive mul